The Baker Brothers are considered a powerhouse in the biotech world, renowned for their razor-sharp focus on life sciences and high-conviction bets.

Run by Julian and Felix Baker, Baker Brothers Advisors currently has over $20 billion in assets under management. Over the years, they've carved out a reputation as the kingmakers of biotech, turning early-stage companies into industry disruptors.

Their biggest winner, an investment in Seattle Genetics, resulted in a windfall of over $8 billion when it was bought by Pfizer in 2023. Simply put: when the Baker Brothers invest in a stock, we listen. 

So we put together this special report of some of their recent purchases. Do we want to own them? We'll let the chart tell us.